AZI2

Summary

AZI2 (5-azacytidine induced 2, HGNC:24002) is a protein-coding gene on chromosome 3p24.1, encoding 5-azacytidine-induced protein 2 (Q9H6S1). Adapter protein which binds TBK1 and IKBKE playing a role in antiviral innate immunity.

AZI2, or NAP1, contributes to the activation of NFKB (see MIM 164011)-dependent gene expression by activating IKK-related kinases, such as NAK (TBK1; MIM 604834) (Fujita et al., 2003 [PubMed 14560022]).

Source: NCBI Gene 64343 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 58 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_022461

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24002
Approved symbol	AZI2
Name	5-azacytidine induced 2
Location	3p24.1
Locus type	gene with protein product
Status	Approved
Aliases	NAP1, FLJ21939, AZ2
Ensembl gene	ENSG00000163512
Ensembl biotype	protein_coding
OMIM	609916
Entrez	64343

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 19 protein_coding, 6 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000295748, ENST00000334100, ENST00000414162, ENST00000415852, ENST00000420543, ENST00000429369, ENST00000457172, ENST00000462936, ENST00000463512, ENST00000470234, ENST00000476174, ENST00000479665, ENST00000488978, ENST00000492044, ENST00000889265, ENST00000889266, ENST00000889267, ENST00000889268, ENST00000889269, ENST00000889270, ENST00000912521, ENST00000958175, ENST00000958176, ENST00000958177, ENST00000958178, ENST00000958179

RefSeq mRNA: 4 — MANE Select: NM_022461 NM_001134432, NM_001134433, NM_001271650, NM_022461

CCDS: CCDS2647, CCDS46782, CCDS46783

Canonical transcript exons

ENST00000479665 — 8 exons

Exon	Start	End
ENSE00001839362	28321047	28324454
ENSE00003481784	28336737	28336885
ENSE00003483722	28338493	28338615
ENSE00003560852	28340402	28340622
ENSE00003576368	28326832	28326950
ENSE00003629457	28337937	28338036
ENSE00003784409	28332369	28332427
ENSE00003841512	28348601	28348824

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 96.61.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.5980 / max 260.9960, expressed in 1824 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
41549	18.2965	1816
41547	12.7444	1739
41544	1.0025	659
41546	0.9732	611
41541	0.3755	96
41543	0.3630	123
41542	0.3509	105
41548	0.2705	110
41545	0.2215	83

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	96.61	gold quality
monocyte	CL:0000576	96.45	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.45	gold quality
calcaneal tendon	UBERON:0003701	96.32	gold quality
omental fat pad	UBERON:0010414	96.22	gold quality
peritoneum	UBERON:0002358	96.19	gold quality
buccal mucosa cell	CL:0002336	96.17	gold quality
mucosa of stomach	UBERON:0001199	96.15	gold quality
right lung	UBERON:0002167	96.03	gold quality
lower lobe of lung	UBERON:0008949	96.01	gold quality
mononuclear cell	CL:0000842	95.89	gold quality
adipose tissue of abdominal region	UBERON:0007808	95.89	gold quality
leukocyte	CL:0000738	95.73	gold quality
ganglionic eminence	UBERON:0004023	95.36	gold quality
ventricular zone	UBERON:0003053	95.23	gold quality
adenohypophysis	UBERON:0002196	95.12	gold quality
endocervix	UBERON:0000458	95.04	gold quality
upper lobe of left lung	UBERON:0008952	95.00	gold quality
upper lobe of lung	UBERON:0008948	94.98	gold quality
left coronary artery	UBERON:0001626	94.97	gold quality
pituitary gland	UBERON:0000007	94.91	gold quality
colonic epithelium	UBERON:0000397	94.87	gold quality
tibial artery	UBERON:0007610	94.86	gold quality
popliteal artery	UBERON:0002250	94.85	gold quality
nerve	UBERON:0001021	94.82	gold quality
tibial nerve	UBERON:0001323	94.82	gold quality
gall bladder	UBERON:0002110	94.79	gold quality
adrenal tissue	UBERON:0018303	94.76	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.73	gold quality
ectocervix	UBERON:0012249	94.72	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	12.99

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 7)

• These results define NAK-associated protein 1 (NAP1) as an activator of IkappaB kinase-related kinases and suggest that the NAK-NAP1 complex may protect cells from TNF-alpha-induced apoptosis by promoting NF-kappaB activation. (PMID:14560022)
• Both the cytoplasmic and TLR3-mediated dsRNA recognition pathways converge upon NAP1 for the activation of the IRF-3 and IFN-beta promoter. (PMID:17142768)
• the spatiotemporal mobilization of TICAM-1 in response to dsRNA and the formation of the TICAM-1 speckles containing RIP1 and NAP1 are important for the activation of the TLR3-TICAM-1 pathway. (PMID:17982077)
• (AZI2)3’UTR confers variant-dependent transcriptional regulation of SLC6A3, a potential risk factor for substance abuse disorders. (PMID:28983843)
• AZI2 mediates TBK1 activation at unresolved selective autophagy cargo receptor complexes with implications for CD8 T-cell infiltration in breast cancer. (PMID:37733921)
• NAK-associated protein 1/NAP1 activates TBK1 to ensure accurate mitosis and cytokinesis. (PMID:38059900)
• TBK1 adaptor AZI2/NAP1 regulates NDP52-driven mitochondrial autophagy. (PMID:39276928)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	azi2	ENSDARG00000102419
mus_musculus	Azi2	ENSMUSG00000039285
rattus_norvegicus	Azi2	ENSRNOG00000010096

Paralogs (1): TBKBP1 (ENSG00000198933)

Protein

Protein identifiers

5-azacytidine-induced protein 2 — Q9H6S1 (reviewed: Q9H6S1)

Alternative names: NF-kappa-B-activating kinase-associated protein 1, TILP

All UniProt accessions (4): C9JGA2, C9JVK8, Q9H6S1, H7C1Z1

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein which binds TBK1 and IKBKE playing a role in antiviral innate immunity. Activates serine/threonine-protein kinase TBK1 and facilitates its oligomerization. Enhances the phosphorylation of NF-kappa-B p65 subunit RELA by TBK1. Promotes TBK1-induced as well as TNF or PMA-induced activation of NF-kappa-B. Participates in IFNB promoter activation via TICAM1.

Subunit / interactions. Homodimer. Interacts with IKBKE. Interacts with TBK1. Interacts with TICAM1. Interacts with TAX1BP1. Interacts with CALCOCO2. (Microbial infection) Interacts with vaccinia virus protein C6.

Subcellular location. Cytoplasm.

Tissue specificity. Widely expressed. Abundant expression seen in the pancreas and testis.

Post-translational modifications. Ubiquitinated via ‘Lys-48’-linked polyubiquitination by TRIM38, leading to its degradation.

Isoforms (4)

UniProt ID	Names	Canonical?
Q9H6S1-1	1, Long	yes
Q9H6S1-3	2, Short
Q9H6S1-4	3
Q9H6S1-5	4

RefSeq proteins (4): NP_001127904, NP_001127905, NP_001258579, NP_071906* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR024581	TBD	Domain
IPR051891	TBK1-IKBKE_adapters	Family

Pfam: PF12845

UniProt features (17 total): splice variant 6, region of interest 2, strand 2, helix 2, coiled-coil region 2, modified residue 2, chain 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
5EP6	X-RAY DIFFRACTION	1.45
5Z7L	X-RAY DIFFRACTION	2.02
7EA2	X-RAY DIFFRACTION	2.14
5Z7G	X-RAY DIFFRACTION	2.3
7EA7	X-RAY DIFFRACTION	2.69

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6S1-F1	69.50	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 318, 353

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 229 (showing top): GOBP_DENDRITIC_CELL_DIFFERENTIATION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GOBP_RESPONSE_TO_TYPE_I_INTERFERON, FOXO4_01, LA_MEN1_TARGETS, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, EVI1_05, IRF7_01, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_LEUKOCYTE_PROLIFERATION, AML_Q6, GOBP_MITOTIC_CELL_CYCLE, GOBP_NEGATIVE_REGULATION_OF_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN

GO Biological Process (7): mitotic cell cycle (GO:0000278), T cell activation (GO:0042110), negative regulation of canonical NF-kappaB signal transduction (GO:0043124), dendritic cell proliferation (GO:0044565), defense response to virus (GO:0051607), type I interferon-mediated signaling pathway (GO:0060337), dendritic cell differentiation (GO:0097028)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), serine/threonine protein kinase complex (GO:1902554)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell cycle	1
mitotic nuclear division	1
lymphocyte activation	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
negative regulation of intracellular signal transduction	1
mononuclear cell proliferation	1
defense response	1
response to virus	1
cellular response to type I interferon	1
interferon-mediated signaling pathway	1
mononuclear cell differentiation	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
protein kinase complex	1

Protein interactions and networks

STRING

586 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AZI2	IKBKE	Q14164	966
AZI2	TBK1	Q9UHD2	955
AZI2	TANK	Q92844	884
AZI2	TRAF3	Q13114	732
AZI2	IKBKG	Q9Y6K9	682
AZI2	CALCOCO2	Q13137	643
AZI2	IRF3	Q14653	619
AZI2	EXOC2	Q96KP1	599
AZI2	ZBP1	Q9H171	599
AZI2	RALB	P11234	596
AZI2	TBKBP1	A7MCY6	595
AZI2	OTUD5	Q96G74	594
AZI2	IRF7	Q92985	533
AZI2	RB1CC1	Q8TDY2	529
AZI2	CMC1	Q7Z7K0	499

IntAct

49 interactions, top by confidence:

A	B	Type	Score
TBK1	TBKBP1	psi-mi:“MI:0914”(association)	0.860
AZI2	TBK1	psi-mi:“MI:0915”(physical association)	0.810
CALCOCO2	TBKBP1	psi-mi:“MI:0914”(association)	0.640
CALCOCO2	AZI2	psi-mi:“MI:0914”(association)	0.640
TBK1	TTC4	psi-mi:“MI:0914”(association)	0.540
APBA3	DUSP11	psi-mi:“MI:0914”(association)	0.530
BBOX1	ITPRID2	psi-mi:“MI:0914”(association)	0.530
APBA3	CLSTN1	psi-mi:“MI:0914”(association)	0.530
OPG029	AZI2	psi-mi:“MI:0915”(physical association)	0.520
AZI2	OPG029	psi-mi:“MI:0915”(physical association)	0.520
	AZI2	psi-mi:“MI:0915”(physical association)	0.510
NAA10	OFD1	psi-mi:“MI:0914”(association)	0.480
GABARAP	AZI2	psi-mi:“MI:0407”(direct interaction)	0.440
GABARAPL1	AZI2	psi-mi:“MI:0407”(direct interaction)	0.440
GABARAPL2	AZI2	psi-mi:“MI:0407”(direct interaction)	0.440
TNFAIP3	LRRIQ3	psi-mi:“MI:2364”(proximity)	0.420
AZI2	IKBKE	psi-mi:“MI:0915”(physical association)	0.400
AZI2		psi-mi:“MI:0915”(physical association)	0.370
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350
	TBKBP1	psi-mi:“MI:0914”(association)	0.350
	AHRR	psi-mi:“MI:0914”(association)	0.350
TBK1	FMNL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (87): AZI2 (Affinity Capture-Western), TRIM38 (Affinity Capture-Western), AZI2 (Affinity Capture-MS), AZI2 (Affinity Capture-MS), AZI2 (Affinity Capture-MS), AZI2 (Affinity Capture-MS), AZI2 (Two-hybrid), AZI2 (Affinity Capture-MS), AZI2 (Affinity Capture-MS), AZI2 (Affinity Capture-Western), AZI2 (Affinity Capture-MS), TBK1 (Co-crystal Structure), TBK1 (Reconstituted Complex), AZI2 (Affinity Capture-MS), AZI2 (Co-crystal Structure)

ESM2 similar proteins: A0A088MLT8, A2AQ25, B3KU38, B5DF41, E9PSK7, O15079, O35274, P0DPB3, P0DPB4, P12755, P49140, P85299, Q0D2I5, Q14DQ1, Q1LY51, Q3B7M3, Q3SYW5, Q4KMA0, Q4R3X1, Q50H33, Q5F3L9, Q5FVG6, Q5RD40, Q5XKK7, Q60698, Q6ZNC4, Q6ZUS6, Q6ZWB6, Q80U23, Q80U62, Q80XA6, Q812A5, Q86YI8, Q8BXL9, Q8K2W6, Q8ND83, Q8NFH8, Q8QFX1, Q8TEK3, Q924W7

Diamond homologs: A2A9T0, A7MCY6, Q3SYW5, Q4KMA0, Q4R3X1, Q5RD40, Q6DG50, Q9H6S1, Q9QYP6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 37 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TNFR1-induced proapoptotic signaling	5	95.5×	1e-07
Regulation of TNFR1 signaling	7	68.2×	1e-09

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of canonical NF-kappaB signal transduction	5	11.7×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	48
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
57397	GRCh38/hg38 3p26.3-22.2(chr3:52266-37148076)x3	Pathogenic

SpliceAI

2213 predictions. Top by Δscore:

Variant	Effect	Δscore
3:28316419:GCTTA:G	donor_gain	1.0000
3:28316420:CTTA:C	donor_gain	1.0000
3:28316421:TTA:T	donor_gain	1.0000
3:28316422:TA:T	donor_gain	1.0000
3:28316423:AG:A	donor_loss	1.0000
3:28316424:G:C	donor_loss	1.0000
3:28316424:G:GG	donor_gain	1.0000
3:28316425:TAA:T	donor_loss	1.0000
3:28316426:AA:A	donor_loss	1.0000
3:28319622:GCAT:G	donor_gain	1.0000
3:28319626:G:GG	donor_gain	1.0000
3:28319653:G:GT	donor_gain	1.0000
3:28319654:A:T	donor_gain	1.0000
3:28319670:G:GT	donor_gain	1.0000
3:28319670:G:T	donor_gain	1.0000
3:28324451:CAGG:C	acceptor_gain	1.0000
3:28324455:C:CC	acceptor_gain	1.0000
3:28336784:T:A	donor_gain	1.0000
3:28336881:CATCA:C	acceptor_gain	1.0000
3:28336883:TCA:T	acceptor_gain	1.0000
3:28336884:CA:C	acceptor_gain	1.0000
3:28336884:CAC:C	acceptor_gain	1.0000
3:28336886:C:CC	acceptor_gain	1.0000
3:28337927:A:C	donor_gain	1.0000
3:28337935:AC:A	donor_gain	1.0000
3:28337936:CC:C	donor_gain	1.0000
3:28337936:CCCTG:C	donor_gain	1.0000
3:28338486:AACTT:A	donor_loss	1.0000
3:28338487:ACTTA:A	donor_loss	1.0000
3:28338488:CTT:C	donor_loss	1.0000

AlphaMissense

2583 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:28340463:A:G	L52P	0.999
3:28340496:A:G	L41P	0.999
3:28340496:A:T	L41H	0.999
3:28340471:T:A	K49N	0.998
3:28340471:T:G	K49N	0.998
3:28340488:C:G	A44P	0.998
3:28340499:G:T	A40D	0.998
3:28340501:A:C	F39L	0.998
3:28340501:A:T	F39L	0.998
3:28340503:A:G	F39L	0.998
3:28337963:A:G	L138P	0.997
3:28338542:C:G	R97P	0.997
3:28340466:C:G	R51P	0.997
3:28340485:A:C	Y45D	0.997
3:28340485:A:G	Y45H	0.997
3:28340586:A:G	I11T	0.997
3:28337993:A:G	L128P	0.996
3:28338546:A:C	Y96D	0.996
3:28338555:A:C	Y93D	0.996
3:28340487:G:T	A44E	0.996
3:28337972:A:G	L135P	0.995
3:28338549:C:G	A95P	0.995
3:28340472:T:A	K49I	0.995
3:28340583:A:G	L12P	0.995
3:28340455:A:G	S55P	0.994
3:28340479:C:G	D47H	0.994
3:28340496:A:C	L41R	0.994
3:28340502:A:G	F39S	0.994
3:28340504:A:C	H38Q	0.994
3:28340504:A:T	H38Q	0.994

dbSNP variants (sampled 300 via entrez): RS1000248644 (3:28331787 T>C), RS1000423212 (3:28325061 GAA>G), RS1000563047 (3:28323104 TTCTC>T), RS1000812479 (3:28343133 A>G), RS1000968253 (3:28335727 T>C), RS1000990811 (3:28330408 C>A,T), RS1001165603 (3:28337060 G>A,C), RS1001177809 (3:28335563 G>A), RS1001215033 (3:28328226 T>G), RS1001379073 (3:28345673 GA>G,GAA), RS1001490990 (3:28349460 G>C), RS1001662363 (3:28320753 A>G), RS1001674300 (3:28328622 T>C), RS1001742773 (3:28342768 A>C), RS1001966026 (3:28323975 T>A)

Disease associations

OMIM: gene MIM:609916 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003901_9	Cognitive decline (age-related)	1.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523456 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

5 potent at pChembl≥5 of 5 total, top 5 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.57	Kd	26.91	nM	CHEMBL3752910
7.42	ED50	38.34	nM	CHEMBL3752910
5.53	Kd	2982	nM	CHEMBL4462318
5.34	Kd	4543	nM	CHEMBL5653589
5.19	ED50	6473	nM	CHEMBL5653589

PubChem BioAssay actives

3 with measured affinity, of 5 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147934: Binding affinity to human AZI2 incubated for 45 mins by Kinobead based pull down assay	kd	0.0269	uM
2,6-difluoro-N-[3-fluoro-4-[6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl]oxyphenyl]benzenesulfonamide	1573326: Binding affinity to AZI2 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	kd	2.9820	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147934: Binding affinity to human AZI2 incubated for 45 mins by Kinobead based pull down assay	kd	4.5429	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, increases expression	5
Cyclosporine	increases expression	3
sodium arsenite	decreases expression	2
cobaltous chloride	increases expression	2
Air Pollutants	decreases expression, increases abundance	2
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
decabromobiphenyl ether	affects expression	1
trichostatin A	affects cotreatment, decreases expression	1
beta-lapachone	increases expression	1
ochratoxin A	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	decreases expression	1
Decitabine	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Cannabidiol	increases expression	1
Clorgyline	increases expression	1
Coal	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	decreases expression, affects cotreatment	1
Methyl Methanesulfonate	decreases expression	1
Smoke	increases abundance, decreases expression	1
Theophylline	affects cotreatment, decreases expression	1
Thimerosal	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4371456	Binding	Binding affinity to AZI2 in SILAC-labeled human MDA-MB-231 cells lysate by mass spectrometry based kinAffinity assay	Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors. — J Med Chem

Cellosaurus cell lines

10 cell lines: 10 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1KU	Abcam HeLa AZI2 KO	Cancer cell line	Female
CVCL_C8QB	HeLa S3 penta KO-AZI2/TBKBP1 DKO clone 20	Cancer cell line	Female
CVCL_C9DV	HeLa S3 AZI2/TBKBP1 DKO clone 13	Cancer cell line	Female
CVCL_C9DW	HeLa S3 penta KO-ULK1/ULK2 DKO-AZI2/TBKBP1 DKO	Cancer cell line	Female
CVCL_D2Q0	HeLa S3 AZI2/TBKBP1 DKO clone 14	Cancer cell line	Female
CVCL_D2Q1	HeLa S3 penta KO-AZI2/TBKBP1 DKO clone 26	Cancer cell line	Female
CVCL_D2YA	HeLa S3 AZI2 KO clone 32	Cancer cell line	Female
CVCL_D2YB	HeLa S3 AZI2 KO clone 62	Cancer cell line	Female
CVCL_SE40	HAP1 AZI2 (-) 1	Cancer cell line	Male
CVCL_SE41	HAP1 AZI2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.